Back to top
more

GSK PLC Sponsored ADR (GSK)

(Delayed Data from NYSE)

$38.96 USD

38.96
4,990,122

-0.25 (-0.64%)

Updated Oct 17, 2024 04:00 PM ET

After-Market: $38.98 +0.02 (0.05%) 7:58 PM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy23.68%
2Buy17.55%
3Hold9.21%
4Sell4.93%
5Strong Sell2.36%
S&P50010.96%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

A Value C Growth A Momentum A VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 37% (93 out of 250)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Biotech Stock Roundup: DICE Gains on LLY Buyout, MRSN Down on Update & More

by Zacks Equity Research

Acquisition and regulatory updates from DICE and GSK plc (GSK ) are in focus in the biotech sector.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $34.62, moving -1.51% from the previous trading session.

GSK vs. TECH: Which Stock Should Value Investors Buy Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

GSK Announces Extension of FDA Review for Rare Blood Therapy

by Zacks Equity Research

GSK announces the FDA's extension of the review period of its new drug application for momelotinib to treat myelofibrosis by three months. A decision is now expected on Sep 16, 2023.

GSK (GSK) Outpaces Stock Market Gains: What You Should Know

by Zacks Equity Research

GSK (GSK) closed at $34.64 in the latest trading session, marking a +0.73% move from the prior day.

FDA Panel Endorses AstraZeneca (AZN), Sanofi's RSV Antibody

by Zacks Equity Research

The FDA's AMDAC unanimously recommends AstraZeneca (AZN)/Sanofi's (SNY) nirsevimab as full immunization against RSV disease for all infants.

Biotech Stock Roundup: GSK Provides Updates, Biogen to Discontinue Study & More

by Zacks Equity Research

Regulatory and pipeline updates from GSK plc (GSK) and Biogen (BIIB) are in focus in the biotech sector.

GSK (GSK) Dips More Than Broader Markets: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $34.36, moving -0.75% from the previous trading session.

GSK's RSV Vaccine Arexvy Gets EU Approval for Older Adults

by Zacks Equity Research

The approval of GSK's RSV vaccine for older adults is based on positive data from the pivotal AReSVi-006 phase III study.

Are You a Value Investor? This 1 Stock Could Be the Perfect Pick

by Zacks Equity Research

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

GSK (GSK) Gains But Lags Market: What You Should Know

by Zacks Equity Research

In the latest trading session, GSK (GSK) closed at $33.80, marking a +0.6% move from the previous day.

Pfizer's (PFE) RSV Vaccine for Older Adults Gets FDA Approval

by Zacks Equity Research

The FDA approves Pfizer's (PFE) RSV vaccine, Abrysvo, for older adults, making it the second RSV vaccine to be approved by the regulatory agency.

Pfizer's (PFE) RSV Vaccine for Infants Gets FDA Panel Vote

by Zacks Equity Research

The FDA's decision on Pfizer's (PFE) BLA seeking approval for its RSV vaccine candidate in infants through maternal immunization is expected in August.

Neena Mishra headshot

Biotech ETFs Pop on M&A Resurgence

by Neena Mishra

2023 could be a year of heightened biotech dealmaking activity

Ionis (IONS) Q1 Earnings Surpass Estimates, Sales Match

by Zacks Equity Research

Ionis (IONS) reports a narrower-than-expected Q1 loss. Sales come in line with estimates. The company re-affirms its previously issued financial guidance for 2023.

Is WisdomTree Global ex-U.S. Quality Dividend Growth ETF (DNL) a Strong ETF Right Now?

by Zacks Equity Research

Smart Beta ETF report for DNL

Are Medical Stocks Lagging BioRad Laboratories (BIO) This Year?

by Zacks Equity Research

Here is how Bio-Rad Laboratories (BIO) and GSK (GSK) have performed compared to their sector so far this year.

How to Find Strong Medical Stocks Slated for Positive Earnings Surprises

by Zacks Equity Research

The Zacks Earnings ESP is a great way to find potential earnings surprises. Why investors should take advantage now.

Gilead's (GILD) Q1 Earnings Miss, Veklury Sales Plunge

by Zacks Equity Research

Gilead's (GILD) Q1 earnings and sales miss estimates due to lower Veklury sales.

GSK or TECH: Which Is the Better Value Stock Right Now?

by Zacks Equity Research

GSK vs. TECH: Which Stock Is the Better Value Option?

Stock Market News for Apr 27, 2023

by Zacks Equity Research

Wall Street closed mixed on Wednesday.

GSK Beats on Q1 Earnings, Lags Sales, Reaffirms 2023 Outlook

by Zacks Equity Research

Though GSK's revenues benefit from strong growth across all segments, the declining COVID-19 antibody sales do not bode well. Management reaffirms its 2023 guidance.

GSK (GSK) Tops Q1 Earnings Estimates

by Zacks Equity Research

Glaxo (GSK) delivered earnings and revenue surprises of 5.88% and 1.28%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

GSK (GSK) Gains As Market Dips: What You Should Know

by Zacks Equity Research

GSK (GSK) closed the most recent trading day at $36.91, moving +0.71% from the previous trading session.

Mark Vickery headshot

Top Stock Reports for Linde, Vertex Pharmaceuticals & Edwards Lifesciences

by Mark Vickery

Today's Research Daily features new research reports on 16 major stocks, including Linde plc (LIN), Vertex Pharmaceuticals Incorporated (VRTX) and Edwards Lifesciences Corporation (EW).